A development plan for coramsine was approved by the TGA in May 2007 resulting in further pre-clinical studies, which were successfully completed in March 2008. Solbec unsuccessfully sought a business partner to develop coramsine further, abandoning its development, as they changed the company's direction as well as its legal business name in December 2008, following the US investment market's late-2008 turmoil and ensuing credit crunch.
In May 2007, the TGA approved a development plan for coramsine, prompting further pre-clinical studies that were completed successfully in March 2008. However, Solbec failed to secure a business partner to continue developing coramsine, ultimately abandoning its development after changing their company direction and legal name in December 2008 due to the US investment market's turmoil and credit crunch.